Clinical prospects of application of alginate-based agents in the treatment of gastroesophageal reflux disease
Abstract
The aim of review. To assess therapeutic potentials of alginate-based drug («Gaviscon») in treatment of various forms of gastroesophageal reflux disease (GERD).
Original positions. Alginic acids and alginates have several properties that allow to use them in patients with GERD: cytoprotective effect for damaged tissues, the high sorption activity, coating and antireflux action. On the literature data, it was found, that elimination of gastroesophagal reflux starts from first day of intake of the drug , and relief of the main clinical symptoms of GERD – within 2–3 days. Positive therapeutic effect was also found in alkaline refluxes. According to original observation, application of suspension «Gaviscon-forte» in a standard dose (10 ml after meal tid and 10 ml at the bedtime) for 14 days in the majority of patients improves scores of 24-hour pH-monitoring and considerably reduces percent of time with intragastric pH <2 at night-time. Frequency of heartburn attacks decreased, up to complete cessation already from the 2-nd day of treatment. At the end of treatment this symptom has completely stopped. Gaviscon has good organoleptic properties and high safety.
Conclusion. Gaviscon shows high performance in elimination of GERD symptoms and can be recommended as monotherapy for some forms of reflux disease and at any variant of GERD in combination to proton pump inhibitors.
About the Authors
Yu. P. UspenskyRussian Federation
N. V. Baryshnikova
Russian Federation
I. G. Pakhomova
Russian Federation
References
1. Болезни пищевода / Под ред. В.Т. Ивашкина, А.С. Трухманова. – М.: Триада-Х, 2000. – 179 с.
2. Васильев Ю.В., Машарова А.А., Янова О.Б. и др. Опыт применения Гевискона в устранении желудочно-пищеводного рефлюкса у больных гастроэзофагеальной рефлюксной болезнью // Consilium medicum (прил. «Гастроэнтерология»). – 2007. – № 2. – С. 3–5.
3. Лазебник Л.Б., Васильев Ю.В. Проект. Терапия кислотозависимых заболеваний (Первое Московское соглашение, 5 февраля 2003 г.) // Эксп. клин. гастроэнтерол. – 2003. – № 4. – С. 3–18.
4. Пасечников В.Д. Функциональная изжога – проявление неэрозивной рефлюксной болезни или нарушение висцерального восприятия в пищеводе? // Consilium medicum. – 2003. – Т. 5, № 6. – С. 312–318.
5. Профилактика и лечение хронических заболеваний верхних отделов желудочно-кишечного тракта / Под ред. В.Т. Ивашкина. – М., 2002. – 128 с.
6. Успенский Ю.П., Пахомова И.Г., Бубякина В.Н. Патогенетическое обоснование перспектив клинического использования альгинатсодержащего препарата «Гевискон» у пациентов с хроническим панкреатитом, сочетающимся с гастроэзофагеальной рефлюксной болезнью // Рус. мед. журн. – 2007. – Т. 15, № 28. – С. 1–5.
7. Успенский Ю.П., Пахомова И.Г., Ткаченко Е.И. Первый в России опыт использования «Гевискона» в лечении гастроэзофагеальной рефлюксной болезни // Рус. мед. журн. – 2007. – Т. 15, № 22. – С. 1–4.
8. Хауг А. Методы химии углеводов: пер. с англ. – М., 1967. – С. 317–321.
9. Berthon G. Aluminum speciation in relation to aluminum bioavailability, metabolism and toxiety // Coord Ghem Rev. – 2002. – Vol. 228. – P. 319–341.
10. Dent J., Brun J., Fendrick A. et al. An evidence based appraisal of reflux disease management // Genval Workshop Rep. – 1999. – Vol. 44 (suppl. 2).– Р. 1–16.
11. Kaehny W., Hegg A., Alfrey A. Gastrointestinal absorption of aluminum from aluminum-containing antacids // N. Engl. J. Med. – 1977. – Vol. 296. – P. 1389–1390.
12. Laheij R., Stukenboom M., Nassing R. et al. Risk of community-acquired pneumonia and use gastric acid-suppressive drugs // JAMA. – 2004. – Vol. 292. – P. 1955–1960.
13. Lindow S.W., Regnйll P., Sykes J., Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy // Int. J. Clin. Pract. – 2003. – Vol. 57, N 3. – P. 175–179.
14. Yamada Masanori Alginic acid-imidazole composite material as anhydrous proton conducting membrane // Honma Itaru. Polym. – 2004. – Vol. 45, N 25. – P. 8349–8354.
15. Yang Y., Lewis J., Epstein S., Metz D. Long-term proton pump inhibitor therapy and risk of hip fraction // JAMA. – 2006. – Vol. 296. – P. 2947–2953.
Review
For citations:
Uspensky Yu.P., Baryshnikova N.V., Pakhomova I.G. Clinical prospects of application of alginate-based agents in the treatment of gastroesophageal reflux disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2009;19(2):79-84. (In Russ.)
Views:
8
Email this article 
